Brief Description
The study assesses the efficacy and safety of extended TARPEYO® treatment in adult participants who have completed 9 months of TARPEYO 16 mg daily treatment. The study treatment period is 15 months; TARPEYO 16 mg daily dose will be taken for 6-months followed by 8 mg daily dose for 9-months.
Trial Physician / Study Coordinator
Laurie Jones
Estimated Enrollment
60
Estimated End Date
04/2027
Trial is for people with
Patients on current TARPEYO treatment
Study Goal
NefXtend seeks to assess the treatment benefit on kidney function (UPCR, eGFR, 24-hour proteinuria, and microhematuria) as well as ...
What is involved for the patient?
Patients consenting to study participation will complete screening assessments prior to stopping their current TARPEYO treatment. ...
About the drug or intervention
TARPEYO® is recommended as a 9-month treatment. The extended use of TARPEYO in this clinical study is investigational.